Pancreatic Cancer Trial, Recruiting NCT05939063 Sponsor: Fudan University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05939063
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with pancreatic cancer on the left side of the pancreas that doctors have determined can be removed with surgery.
  • People whose tumor measures 4 cm (about 1.5 inches) or less in size on imaging scans.
  • People whose tumor is located at least 1 cm away from a major blood vessel near the pancreas called the celiac trunk.
  • People whose tumor has not grown into the layer of tissue behind the pancreas.
  • People who are able to follow the study procedures as required by the research protocol.
  • People who are willing to take part voluntarily and have signed a consent form agreeing to participate.

Who may not be able to join:

  • People who have already received treatment before surgery to shrink the tumor (such as chemotherapy or radiation given prior to an operation).
  • People whose cancer has spread to the liver or to other parts of the body.
  • People who have cancer appearing in more than one location, or whose cancer has come back after previous treatment.
  • People who have a history of any other type of cancer.
  • People who are currently taking part in another clinical trial at the same time.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xianjun Yu, MD, PhD, Fudan University

Phone: +86-13801669875

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 October 2023
Est. completion
31 August 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

R0 retroperitoneal margin rate; R0 transection margin rate; Lymph node positive rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov